This is a working overview of Visceral adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== Behavior == Not much is known about N. christyi. However, it is believed to be active by day and night. It is a semi-aquatic snake which spends much of its time in the water. An excellent swimmer. It tends to hide amongst rocks, in holes or overhanging tree roots at the shore line. It also makes use of any man-made structures such as bridges and jetties to hide. Generally this is not an aggressive snake, so bites are rare. If approached in water it will swim away swiftly. If threatened on land it will rear up, spread its narrow hood and hiss. It may strike if it's provoked extensively.
===== Domestic electrical installation ===== Ground fault interrupters are available to reduce electric fields and (in the case of current flow) magnetic fields from residential electrical installations. In plaster installations, only a small part of the electric field can escape from the wall. However, a mains disconnect switch automatically disconnects the relevant line as long as no electrical load is switched on; as soon as a load is switched on, the mains voltage is also switched on. Ground fault interrupters were introduced in 1973 and have been continuously improved over the decades. In 1990, for example, it became possible to disconnect the PEN conductor (formerly known as the neutral conductor). Circuit breakers can be installed in several different circuits, preferably in those that supply bedrooms. However, they only turn off when no continuous current consumers such as air conditioners, fans, humidifiers, electric alarm clocks, night lights, standby devices, alarm systems, chargers, and similar devices are turned on. Instead of the mains voltage, a low voltage (2-12 volts) is applied, which can be used to detect when a consumer is switched on. Rooms can also be shielded with copper wallpaper or special wall paints containing metal, thus applying the Faraday cage principle.
Peptidoglycan, murein or mucopeptide is a unique large macromolecule, a polysaccharide, consisting of sugars and amino acids that forms a mesh-like layer (sacculus) that surrounds the bacterial cytoplasmic membrane. The sugar component consists of alternating residues of β-(1,4) linked N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM). Attached to the N-acetylmuramic acid is an oligopeptide chain made of three to five amino acids. The peptide chain can be cross-linked to the peptide chain of another strand forming the 3D mesh-like layer. Peptidoglycan serves a structural role in the bacterial cell wall, giving structural strength, as well as counteracting the osmotic pressure of the cytoplasm. This repetitive linking results in a dense peptidoglycan layer which is critical for maintaining cell form and withstanding high osmotic pressures, and it is regularly replaced by peptidoglycan production. Peptidoglycan hydrolysis and synthesis are two processes that must occur in order for cells to grow and multiply, a technique carried out in three stages: clipping of current material, insertion of new material, and re-crosslinking of existing material to new material. The peptidoglycan layer is substantially thicker in gram-positive bacteria (20 to 80 nanometers) than in gram-negative bacteria (7 to 8 nanometers). Depending on pH growth conditions, the peptidoglycan forms around 40 to 90% of the cell wall's dry weight of gram-positive bacteria but only around 10% of gram-negative strains.
== Genetics == The genetics of Bruck syndrome differs from osteogenesis imperfecta. Osteogenesis imperfecta usually involves autosomal dominant mutations to COL1A1 or COL1A2 which encode type 1 procollagen. Bruck syndrome is linked to mutations in two genes, and therefore is divided in two types. Bruck syndrome type 1 is caused by a homozygous mutation in the FKBP10 gene. Type 2 is caused by a homozygous mutation in the PLOD2 gene.
Sources: en.wikipedia.org
== Ecology == In southern Rajasthan, many of the hills are well-clad with vegetation, and there, Euphorbia caducifolia is associated with Butea monosperma, Millettia pinnata, Syzygium hyrianium, Wrightia tinctoria and Ziziphus nummularia. In the arid region near Sambhar Salt Lake, it is associated with thorny scrub such as Anogeissus pendula and Boswellia.
Vaccinations will begin in March in Scotland, early April in England and Wales, and mid-April in Northern Ireland. RMT staff working for Network Rail call off a strike planned for 16 March after being given a fresh pay offer. 8 March The UK experiences its coldest March night since 2010, with −15.2 °C recorded in Kinbrace, Scotland, dipping even further to −15.4 °C by the morning. The Health Security Agency issues a level 3 cold alert for the whole of England, while more than 100 schools across Wales are closed due to snow. The National Institute for Health and Care Excellence (NICE) approves the use of the weight loss drug semaglutide (marketed as Wegovy) by the NHS in England. 9 March The UK government announces a two-year delay in the construction of the Birmingham to Crewe leg of HS2 in order to save costs. Asda and Morrisons lift their restrictions on the sale of fresh produce. Following a trial at the High Court in Aberdeen, retired research scientist Christopher Harrison, 82, is convicted of the murder of his ex-wife, Brenda Page, in 1978. 10 March The UK economy grew by 0.3% in January 2023, official figures show, much more than the 0.1% that was predicted by economists. The King bestows the title of Duke of Edinburgh on his younger brother, Prince Edward. Prime Minister Rishi Sunak attends a summit in Paris with French president Emmanuel Macron and announces the UK will give France £500m over three years to help the UK stop the influx of migrants arriving by boat.
Information including the measured mass of the putative peptide ions and those of their fragment ions is then matched against calculated mass values from the conceptual (in-silico) proteolysis and fragmentation of databases of protein sequences. A successful match will be found if its score exceeds a threshold based on the analysis parameters. Even if the actual protein is not represented in the database, error-tolerant matching allows for the putative identification of a protein based on similarity to homologous proteins. A variety of software packages are available to perform this analysis. Software packages usually generate a report showing the identity (accession code) of each identified protein, its matching score, and provide a measure of the relative strength of the matching where multiple proteins are identified. A diagram of the matched peptides on the sequence of the identified protein is often used to show the sequence coverage (% of the protein detected as peptides). Where the POI is thought to be significantly smaller than the matched protein, the diagram may suggest whether the POI is an N- or C-terminal fragment of the identified protein.
In the 1960s, Australia - particularly Queensland - launched the first awareness campaign on the dangers of ultraviolet (UV) radiation in the spirit of primary prevention. In the 1980s, many countries in Europe and overseas initiated similar UV protection campaigns. UV radiation has a thermal effect on the skin and eyes and can lead to skin cancer (malignant melanoma) and eye inflammation or cataracts. To protect the skin from harmful UV radiation, such as photodermatosis, acne aestivalis, actinic keratosis or urticaria solaris, normal clothing, special UV protective clothing (SPF 40-50) and high SPF sunscreen can be used. The Australian-New Zealand Standard (AS/NZS 4399) of 1996 measures new textile materials in an unstretched and dry state for the manufacture of protective clothing worn while bathing, especially by children, and for the manufacture of shading textiles (sunshades, awnings). The UV Standard 801 assumes a maximum radiation intensity with the solar spectrum in Melbourne, Australia, on January 1 of a year (at the height of the Australian summer), the most sensitive skin type of the wearer, and under wearing conditions. As the solar spectrum in the northern hemisphere differs from that in Australia, the measurement method according to the European standard EN 13758-1 is based on the solar spectrum of Albuquerque (New Mexico, USA), which corresponds approximately to that of southern Europe. To protect your eyes, wear sunglasses with UV protection or special goggles that also shield the sides to prevent snow blindness.
== Chemical synthesis == N-Acyl dehydroalanine derivatives have been synthesized by dehydration of serines using a tert-butoxycarbonate leaving group, or by conversion of Cysteine derivatives using various reagents for the elimination of the Thiol-group. Various protected dehydroamino acids can be produced by electrochemical oxidation of the respective amino acid derivative in methanol. Dehydroalanine derivatives have proven to be useful in late-stage peptide modification, enabling straightforward synthesis of functionally diverse peptides or proteins.
Sources: en.wikipedia.org
An ion trap mass spectrometer may incorporate a Penning trap (Fourier-transform ion cyclotron resonance), Paul trap or the Kingdon trap. The Orbitrap, introduced in 2005, is based on the Kingdon trap. Other types of mass spectrometers may also use a linear quadrupole ion trap as a selective mass filter.
=== Shock === Methylene blue increases blood pressure in people with vasoplegic syndrome (redistributive shock). It does not improve delivery of oxygen to tissues or decrease mortality. Methylene blue has been used in calcium channel blocker toxicity as a possible rescue therapy for distributive shock unresponsive to first-line agents. Limited to case reports, a 2024 review found low-quality evidence that methylene blue may reduce short-term mortality, duration of the need for vasopressors, and length of hospital stay.
=== Well-being measurement === Different ways of measuring well-being reveal different contributing factors. The correlation between two of these, life satisfaction and happiness, in the World Values Survey (1981–2005) is only 0.47. These are different, but related concepts which are used interchangeably outside of academia. Typically, life satisfaction, or evaluative wellbeing is measured with Cantril's self-anchoring ladder, a questionnaire where wellbeing is rated on a scale from 1–10. Happiness or hedonic/Affective well-being measurement is measured with the positive and negative affect schedule (PANAS), a more complex scale.
H2N-CO-NH2 → HNCO + NH3 H2N-CO-NH2 + HNCO → H2N-CO-NH-CO-NH2 H2N-CO-NH-CO-NH2 + HNCO → H2N-CO-NH-CO-NH-CO-NH2 As temperature exceeds 190 °C (374 °F), other reactions begin to dominate the process. The first appearance of ammeline occurs prior to 225 °C (437 °F) and is suspected also to occur from decomposition of biuret but is produced at a lower rate than that of CYA or ammelide.
== Geography and transport == Adisham railway station, Kent, England, station code Admiralty MRT station, Singapore, abbreviation Admiralty station (MTR), Hong Kong, station code Ardmore station (Oklahoma), Amtrak, station code
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.